Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Public ClinicalTrials.gov record NCT02615067. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active surveillance and are undergoing voluntary radical prostatectomy (RP) \[Cohort A\] or routine prostate biopsy \[Cohort B\]. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to correctly identify subjects with previously unknown clinically significant prostate cancer.
Study identification
- NCT ID
- NCT02615067
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 531 participants
Conditions and interventions
Conditions
Interventions
- 99mTc-MIP-1404 Injection Drug
- Whole-Body Planar and pelvic SPECT/CT scan Diagnostic Test
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2015 (Type not available)
- Primary completion
- Dec 28, 2017 (Actual)
- Completion
- Dec 28, 2017 (Actual)
- Last update posted
- Apr 10, 2019
2015 – 2017
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Cancer Center | Duarte | California | 91010 | — |
| VA Greater Los Angeles Healthcare | Los Angeles | California | 90073 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Florida Urology Partners - Tampa Bay | Clearwater | Florida | 33612 | — |
| Morton Plant Hospital | Clearwater | Florida | 33765 | — |
| University of Georgia / Regents Medical Center | Augusta | Georgia | 30912 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Louisiana State University Health Science Center | Shreveport | Louisiana | 71103 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Montgomery General Hospital | Olney | Maryland | 20832 | — |
| Lahey Clinic | Burlington | Massachusetts | 01805 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Cooper Health System | Camden | New Jersey | 08103 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| Northeast Urology Research | Concord | North Carolina | 28025 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Oklahoma Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Urologic Consultants of Southeastern PA, LLP | Bala-Cynwyd | Pennsylvania | 19004 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104-2640 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Rockledge | Pennsylvania | 19046 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29435 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington School of Medicine | Seattle | Washington | 98109 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02615067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 10, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02615067 live on ClinicalTrials.gov.